MedTrace Logo

A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia

NCT05225558 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-05-06

Study results available
· View outcomes & findings →

Summary

The objectives of this study is to exploratory whether Vancomycin + Delpazolid is more effective to the standard of treatment (Vancomycin)/ for hospitalized adults with MRSA bacteraemia.

Conditions

  • MRSA Bacteremia

Interventions

DRUG

Delpazolid

BID, PO

DRUG

Vancomycin

IV infusion per 2020 IDSA guideline

DRUG

Placebo of Delpazolid

BID, PO

Sponsors & Collaborators

  • LigaChem Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Hongbin Kim · Seoul National University Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-26
Primary Completion
2024-02-21
Completion
2024-03-18
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05225558 on ClinicalTrials.gov